4D Molecular Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders
Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances at December 31, 2021 | 32,224,524 | $3 | $526,523 | $(423) | $(206,996) | $319,107 |
| Issuance of common stock upon exercise of stock options and warrants | 291,629 | — | 2,466 | — | — | 2,466 |
| Stock-based compensation expense | — | — | 17,121 | — | — | 17,121 |
| Issuance of common stock - 2020 ESPP | 110,474 | — | 823 | — | — | 823 |
| Vesting of common stock warrants issued for services | — | — | 87 | — | — | 87 |
| Net unrealized loss on marketable securities | — | — | — | (773) | — | (773) |
| Net loss | — | — | — | — | (107,494) | (107,494) |
| Balances at December 31, 2022 | 32,626,627 | $3 | $547,020 | $(1,196) | $(314,490) | $231,337 |
| Issuance of common stock upon exercise of stock options and warrants | 574,740 | — | 7,310 | — | — | 7,310 |
| Issuance of common stock for the ATM offering program | 1,098,612 | — | 19,348 | — | — | 19,348 |
| ATM offering costs | — | — | (680) | — | — | (680) |
| Issuance of common stock upon public offering, net of issuance costs | 8,625,000 | 1 | 129,207 | — | — | 129,208 |
| Stock-based compensation expense | — | — | 19,665 | — | — | 19,665 |
| Issuance of common stock - 2020 ESPP | 150,239 | — | 1,178 | — | — | 1,178 |
| Vesting of common stock warrants issued for services | — | — | 88 | — | — | 88 |
| Net unrealized gain on marketable securities | — | — | — | 1,212 | — | 1,212 |
| Net loss | — | — | — | — | (100,837) | (100,837) |
| Balances at December 31, 2023 | 43,075,218 | $4 | $723,136 | $16 | $(415,327) | $307,829 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.